Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

[CMP] [cell line] [SIDM00926] Lung Non-Small Cell Carcinoma

ABSTRACT:

SUBMITTER:

PROVIDER: S-CMO763 | biostudies-other |

REPOSITORIES: biostudies-other

ACCESS DATA

Json Xml

Similar Datasets

A Non-Conventional Platinum Drug against a Non-Small Cell Lung Cancer Line.

Project description: Not available

| S-EPMC9964417 | biostudies-literature

Sotorasib as First-Line Treatment for Advanced KRAS G12C-Mutated Non-Small Cell Lung Carcinoma: A Case Report.

Project description: Not available

| S-EPMC10064287 | biostudies-literature

Profiling non-small cell lung carcinoma cell line PC9 treated with erlotinib

Project description:The non-small cell lung carcinoma (NSCLC) PC9 cell line is an established preclinical model for tyrosine kinase inhibitors. To be able to better understand the differences in response between individual cells, we performed treatment of PC9 cells grown in cell culture with erlotinib followed by Drop-seq. We were able to clearly distinguish cells that were treated with the drug for five different time points from untreated cells, and we discovered different cell populations within the treated cells, likely reflecting heterogeneity of drug resistant cells. We were able to identify specific biomarkers, as preferentially expressed genes, for each cell population. The results of our study will address preexisting and acquired drug resistance that limits clinical usefulness of targeted strategies, particularly in NSCLC.

2020-12-19 | GSE134839 | GEO

Profiling non-small cell lung carcinoma cell line HCC827 treated with erlotinib

Project description:The non-small cell lung carcinoma (NSCLC) HCC827 cell line is an established preclinical model for tyrosine kinase inhibitors. To be able to better understand the differences in response between individual cells, we performed treatment of HCC827 cells grown in cell culture with erlotinib followed by Drop-seq. We were able to clearly distinguish cells that were treated with the drug from untreated cells, and we discovered different cell populations within the treated cells, likely reflecting heterogeneity of drug resistant cells. We were able to identify specific biomarkers, as preferentially expressed genes, for each cell population. The results of our study will address preexisting and acquired drug resistance that limits clinical usefulness of targeted strategies, particularly in NSCLC.

2020-12-19 | GSE134837 | GEO

Cetuximab and biomarkers in non-small-cell lung carcinoma.

Project description: Not available

| S-EPMC3421478 | biostudies-literature

Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agent.

Project description: Not available

| S-EPMC5548882 | biostudies-literature

First-line treatment of advanced ALK-positive non-small-cell lung cancer.

Project description: Not available

| S-EPMC5217519 | biostudies-literature

Comprehensive Characterization of Stage IIIA Non-Small Cell Lung Carcinoma.

Project description: Not available